← Leaderboards
Lei Xu
Massachusetts General Hospital
$1,353,153
Attributed
$2,706,306
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $936.9K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$2,706,306 · 2
By mechanism
R01$2,706,306 · 2
Top collaborators
- Jianren Mao3 shared
- Konstantina M Stankovic3 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Vijaya Ramesh$9,458,883
- Gary Jay Brenner$3,851,453
- Xandra Owens Breakefield$30,735,276
- Anat Olga Stemmer-Rachamimov$1,001,767
- Allen C Steere$11,999,334
Others in their field
Other Rising Stars on “Operative Surgical Procedures”
- Luis A Cifuentes · New Mexico State University Las Cruces$7,084,640
- Joshua D. Wythe · Baylor College Of Medicine$3,966,787
- Daniel Francis · Claria Medical, Inc.$3,708,259
- Salwa A Elgebaly · Nour Heart, Inc.$3,582,845
- Stuart Marcus · Sonalasense Inc$3,491,029
- Riccardo Gottardi · Children'S Hosp Of Philadelphia$3,232,467
Research focus
Operative Surgical ProceduresNew Therapeutic TargetEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorInflammationLigandsMouse ModelEfficacy EvaluationEpidermal Growth Factor ReceptorGeneticInfiltrationInflammatoryInsightLoss Of FunctionMacrophageClinical TrialsBone MarrowAmplifiersCompensationExperimental StudyCytokineGrowthDesignChemokinePharmaceutical Preparations
Grant awards (6)
Targeting HMGB1 to improve hearing andenhance therapy for Vestibular Schwannomas$436,908
R01 · FY2025 · DC · contact PI
Co-Targeting IL-6 and EGFRsignaling for the Treatment of Schwannomatosis and Associated Pain$429,559
R01 · FY2025 · NS · contact PI
Co-Targeting IL-6 and EGFRsignaling for the Treatment of Schwannomatosis and Associated Pain$462,970
R01 · FY2024 · NS · contact PI
Targeting HMGB1 to improve hearing andenhance therapy for Vestibular Schwannomas$439,931
R01 · FY2024 · DC · contact PI
Co-Targeting IL-6 and EGFRsignaling for the Treatment of Schwannomatosis and Associated Pain$477,289
R01 · FY2023 · NS · contact PI
Targeting HMGB1 to improve hearing andenhance therapy for Vestibular Schwannomas$459,649
R01 · FY2023 · DC · contact PI